Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country
Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia L...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Wiley Open Access
2022
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/42216/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|